Top Markets
Coin of the day
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
株式のランク #171
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily... Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
株価
$515.86
最終同期: 2026-09-11
時価総額
$130.93B
変化(1日)
0.25%
変化(1年)
30.75%
US
取引 Vertex Pharmaceuticals Incorporated (VRTX)

カテゴリー

Vertex Pharmaceuticals Incorporated(VRTX)の株式分割履歴
Vertex Pharmaceuticals Incorporated株(シンボル:VRTX)は合計で0回の株式分割を実施しました。
最新の株式分割はSep 12, 2026に行われました。
Sep 12, 2026より前に購入されたVRTX株は、現在0VRTX株に相当します。
株式分割一覧
株式分割 分割比率 累積分割比率
提供された日付のデータは十分ではありません。
類似企業または競合他社の株式分割
企業 株式分割の回数 累積分割比率
0 -
NL
0 -
US
1 x3
AU
0 -
CH
1 x100
BE